334 Phase I study of safety and activity of personalized neoantigen-based vaccines in combination with tumor treating fields for newly diagnosed glioblastoma patients

Julia Kodysh; Cansu Cimen Bozkus; Mansi Saxena; Marcia Meseck; Alex Rubinsteyn; Tim O’Donnell; Tin Htwe Thin; Rachel Brody; John Mandeli; Nina Bhardwaj; Adilia Hormigo

doi:10.1136/jitc-2021-SITC2021.334

Article info

Regular and Young Investigator Award Abstracts

Clinical Trials Completed

334 Phase I study of safety and activity of personalized neoantigen-based vaccines in combination with tumor treating fields for newly diagnosed glioblastoma patients

Free

Authors

Julia Kodysh Icahn School of Medicine at Mount Sinai, New York, NY, USA PubMed articles Google scholar articles
Cansu Cimen Bozkus Icahn School of Medicine at Mount Sinai, New York, NY, USA PubMed articles Google scholar articles
Mansi Saxena Icahn School of Medicine at Mount Sinai, New York, NY, USA PubMed articles Google scholar articles
Marcia Meseck Icahn School of Medicine at Mount Sinai, New York, NY, USA PubMed articles Google scholar articles
Alex Rubinsteyn Icahn School of Medicine at Mount Sinai, New York, NY, USA PubMed articles Google scholar articles
Tim O’Donnell Icahn School of Medicine at Mount Sinai, New York, NY, USA PubMed articles Google scholar articles
Tin Htwe Thin Icahn School of Medicine at Mount Sinai, New York, NY, USA PubMed articles Google scholar articles
Rachel Brody Icahn School of Medicine at Mount Sinai, New York, NY, USA PubMed articles Google scholar articles
John Mandeli Icahn School of Medicine at Mount Sinai, New York, NY, USA PubMed articles Google scholar articles
Nina Bhardwaj Icahn School of Medicine at Mount Sinai, New York, NY, USA PubMed articles Google scholar articles
Adilia Hormigo Icahn School of Medicine at Mount Sinai, New York, NY, USA PubMed articles Google scholar articles

Citation

Kodysh J, Bozkus CC, Saxena M, et al

334 Phase I study of safety and activity of personalized neoantigen-based vaccines in combination with tumor treating fields for newly diagnosed glioblastoma patients

Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-SITC2021.334

Publication history

First published November 10, 2021.

Online issue publication

March 30, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password